Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 7/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 7/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 7/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345894 | 0.96 | DPP4 (0.42) | DPP4ITGB3ITGA2BDPP8DPP7 | |
| Trifluoroacetic Acid SCHEMBL4868210 | 0.86 | PRSS1 (0.40) | DPP4ITGB3ITGA2BDPP8DPP7 | |
| SCHEMBL7680995 | 0.84 | CASP1 (0.53) | — | |
| SCHEMBL4862836 | 0.84 | CTSL (0.43) | ECE1 | |
| SCHEMBL4871099 | 0.83 | DPP4 (0.38) | DPP4DPP8DPP7ECE1TLR2 | |
| SCHEMBL6346814 | 0.81 | DPP4 (0.43) | DPP4ITGB3ITGA2BDPP8DPP7 | |
| SCHEMBL4871107 | 0.81 | ATM (0.44) | — | |
| SCHEMBL7683966 | 0.79 | CASP1 (0.49) | — | |
| SCHEMBL7686487 | 0.79 | CASP1 (0.53) | — | |
| SCHEMBL7679831 | 0.78 | CASP1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20050164954-A1 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-07-28 | — | — | US | disclosed |
| US-6900207-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-31 | — | — | US | disclosed |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-08-14 | — | — | US | disclosed |
| EP-1254901-A1 | NITROGEN-CONTAINING 5-MEMBERED CYCLIC COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164954-A1 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ACIN1, CASP7, CASP10 | DPP4 1772/4885ITGB3 3271/4885ITGA2B 2901/4885 |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ACIN1, CASP7, CASP10 | DPP4 1167/4885ITGB3 3299/4885ITGA2B 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.